
|Articles|October 22, 2012
Questions for Medicare in Meningitis Outbreak
Advertisement
Medicare is coming under scrutiny in the meningitis outbreak that has rekindled doubts about the safety of the nation's drug supply.
The giant health insurance program for seniors long ago flagged compounded drugs produced for the mass market without oversight from the Food and Drug Administration as safety risks. In 2007, Medicare revoked coverage of compounded inhaler drugs for lung disease.
Read the full story:
Source: The Associated Press
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
Rescue Therapy With Rozanolixizumab Promising in Triple-Seronegative MG
3
FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome
4
How Effective and Safe Are GLP-1s for Weight Loss?
5














































